COVID-19 Vaccine Tied to Increased Survival in Patients with Cancer
A study has found that for patients with certain types of advanced lung or skin cancer, administration of a SARS-CoV-2 mRNA vaccine within 100 days of starting immune checkpoint inhibitors is associated with increased overall survival.
Study Finds Viral Infections Increase Risk of Heart Attack/Stroke
A new study has found people have an increased risk of major cardiovascular events following viral infections such as SARS-CoV-2, influenza, HIV, hepatitis C and varicella zoster virus.
States Issue Their Own Guidance About COVID-19 Vaccines
Since the U.S. Food and Drug Administration released its 2025-2026 formula approvals on Aug. 2, significantly restricting who can access the vaccines for the first time since their release, several states have issued their own guidance about COVID-19 vaccines.
Study Shows Pfizer’s Updated mRNA COVID-19 Vaccine Elicits Strong Immune Response
Pfizer and BioNTech updated mRNA COVID-19 vaccine for the 2025-2026 season produced strong immune responses, boosting neutralizing antibody levels by at least fourfold in older people and those with underlying medical conditions.
FDA May Revoke Pfizer’s COVID-19 Vaccine for Young, Healthy Children
The U.S. Food and Drug Administration may revoke Pfizer-BioNTech’s emergency use authorization for its COVID-19 vaccine, Comirnaty, for children ages 6 months through 4 years.
FDA Grants Full Approval for Spikevax in Children at Increased Risk of Disease
The U.S. Food and Drug Administration (FDA) has granted full approval for Moderna’s Spikevax (mRNA-1273) COVID vaccine in children 6 months through 11 years who are at an increased risk of the disease.
COVID-19 May Increase IVIG-Resistance in Kids Prior to Developing Kawasaki Disease
A recent study found there is significantly higher intravenous immune globulin (IVIG) resistance among children who contracted COVID-19 before developing Kawasaki disease
Moderna’s Flu Vaccine Shows Positive Late-Stage Trial Results
Moderna’s experimental mRNA-based influenze (flu) vaccine produced a stronger immune response than a currently available vaccine in a late-stage trial, clearing a path forward for the product and the company’s separate combination flu and COVID vaccine.
COVID-19-Influenza Combination and Standalone Influenza Vaccines Generated a Strong Immune Response
In a late-stage trial, Novavax’s experimental COVID-19-influenza combination (CIC) and standalone trivalent hemagglutinin nanoparticle seasonal influenza (tNIV) vaccines generated a strong immune response in adults aged 65 and older, similar to already approved vaccines against the viruses.
Novavax’s COVID-19 Vaccine Approved for Older Adults and At-Risk Individuals
After a six-week delay, the U.S. Food and Drug Administration approved Novavax’s COVID-19 vaccine, but only for people 65 and older and those 12 years and older who have at least one underlying condition, such as asthma, diabetes, lung disease, obesity and pregnancy, that puts them at higher risk of severe illness.